PMID-19669251 – Thymalfasin Plus TACE for Unresectable HCC RCT
Gish RG et al. "Phase II/III randomized, controlled trial of thymalfasin and transarterial chemoembolization for unresectable hepatocellular carcinoma," Hepatology International, 2009;3(3):480-487.
Quick Reference
| Property | Value |
|---|---|
| PMID | 19669251 |
| DOI | N/A |
| Year | 2009 |
| Journal | Hepatology International |
| Study Type | Phase II Randomized Controlled Trial |
| Evidence Level | II |
| Sample | n=25 patients with unresectable HCC |
| Peptide(s) Studied | Thymosin Alpha-1 (thymalfasin/ZADAXIN) |
Key Findings
- Patients receiving TACE + thymosin alpha-1 (thymalfasin) demonstrated markedly superior overall survival compared to TACE alone: median OS 110.3 weeks vs 57.0 weeks
- The combination was well tolerated with no additional toxicity attributable to thymalfasin beyond TACE-related adverse events
- Thymalfasin enhanced anti-tumor immune responses, evidenced by increased T-cell counts and improved immune function markers in the combination arm
- Tumor response rates (partial response + stable disease) favored the combination arm
- The near-doubling of median overall survival (110.3 vs 57.0 weeks) in an unresectable HCC population is clinically remarkable, though the small sample size mandates cautious interpretation
- Quality of life measures were comparable or improved in the combination arm
Study Design
Phase II randomized controlled trial. Patients with unresectable hepatocellular carcinoma were randomized to receive transarterial chemoembolization (TACE) alone or TACE plus subcutaneous thymalfasin (thymosin alpha-1, 1.6 mg twice weekly). Primary endpoint was overall survival.
Limitations
- Very small sample size (n=25) severely limits statistical power and generalizability
- Phase II trial not powered for definitive efficacy conclusions
- Single-center study
- No blinding — open-label design introduces potential assessment bias
- Heterogeneous patient population in terms of tumor burden and liver function
Clinical Relevance
Despite the small sample size, the near-doubling of median overall survival with the addition of thymosin alpha-1 to TACE is a striking signal. This trial supports the concept that immune modulation with thymosin alpha-1 can enhance the efficacy of locoregional cancer therapies. The favorable safety profile makes thymalfasin an attractive candidate for combination strategies in HCC. Larger confirmatory trials are needed, but this provides proof-of-concept for thymosin alpha-1 as a cancer immunotherapy adjunct.
Related
#research #RCT #evidence-level-II #cancer